COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy (MIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00986362
Recruitment Status : Completed
First Posted : September 29, 2009
Results First Posted : February 20, 2014
Last Update Posted : December 17, 2014
Information provided by (Responsible Party):

Brief Summary:
To evaluate the safety and preliminary efficacy of intravitreal microplasmin as an adjunct to conventional vitrectomy for the treatment of pediatric patients.

Condition or disease Intervention/treatment Phase
Vitrectomy Drug: Ocriplasmin Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The MIC (Microplasmin In Children) Trial: A Randomized, Placebo-controlled, Double-masked, Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
Study Start Date : February 2010
Actual Primary Completion Date : December 2011
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Ocriplasmin

Arm Intervention/treatment
Experimental: Ocriplasmin Drug: Ocriplasmin
175µg ocriplasmin intravitreal injection

Placebo Comparator: Placebo Drug: Placebo
Placebo intravitreal injection

Primary Outcome Measures :
  1. Percentage of Eyes With Total Macular Posterior Vitreous Detachment (PVD). [ Time Frame: Beginning of vitrectomy or after application of suction ]
    Percentage of eyes with total macular PVD (to the vascular ridge in eyes with ROP) at the beginning of vitrectomy or after application of suction, as assessed by masked surgeon observation under the operating microscope.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female infants or children 16 years of age or younger
  2. Patient must be a suitable candidate for conventional 2-port or 3-port pars plana vitrectomy
  3. Patient with attached vitreous somewhere in posterior pole
  4. Patient's parent or guardian must be willing and able to comply with follow-up requirements
  5. Patient's parent(s) must sign informed parental permission form and in the case of school-age children the patient must sign assent form

Exclusion Criteria:

  1. Patient diagnosed with Stage 1, 2, 3 or 5 retinopathy of prematurity (ROP) at the time of surgery
  2. Unclear media, which precludes assessment of the posterior pole such as a cataract or vitreal opacity
  3. Active parental/guardian drug or alcohol use or dependence that, in the opinion of the site Investigator, would interfere with parent's or guardian's adherence to study requirements
  4. Medical problems that make consistent follow-up over the treatment period uncertain.
  5. Patient must not have participated in an investigational drug or device study in the prior 30 days
  6. Female Patients of childbearing potential must not be pregnant or lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00986362

Layout table for location information
United States, Michigan
Associated Retina Consultants
Royal Oak,, Michigan, United States, 48073
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: ThromboGenics Identifier: NCT00986362    
Other Study ID Numbers: TG-MV-009
First Posted: September 29, 2009    Key Record Dates
Results First Posted: February 20, 2014
Last Update Posted: December 17, 2014
Last Verified: April 2014
Keywords provided by ThromboGenics:
Safety in pediatrics